Medical/Pharmaceuticals
Wingderm® Shines at IMCAS Asia 2024 with the Innovative Aesthetic Solutions
BEIJING, June 24, 2024 /PRNewswire/ -- From June 21 to 23, IMCAS Asia was held
inBangkok, Thailand. Wingderm®, a provider of medical aesthetic devices, has
garnered significant attention with its innovative aesthetic solutions.
2024-06-24 12:31
1672
Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa
SINGAPORE, June 24, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling...
2024-06-24 09:00
1785
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
ROCKVILLE, Md. and SUZHOU, China, June 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK) announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of Amer...
2024-06-24 08:15
3142
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
BEIJING and BRIDGEWATER, N.J., June 23, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in...
2024-06-23 21:09
2984
Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference
* A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekl...
2024-06-22 07:00
5141
Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer
CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indicated as monotherapy for the treatment of patients with post-transplant l...
2024-06-21 19:28
2375
Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform
BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing)
Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and
Trademark Office (USPTO) patent grant for independently developed RenLite®
fully human common light chain mouse platform.
2024-06-21 17:45
8438
ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment
CHAPEL HILL, N.C., June 21, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), the leading international professional medical-scientific organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosi...
2024-06-21 14:00
1847
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
ROCKVILLE, Md. and SUZHOU, China, June 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has bee...
2024-06-21 09:19
4247
Tobii launches Tobii Nexus - webcam eye tracking for integration into any device or application
TAIPEI, June 20, 2024 /PRNewswire/ -- A software-only integration platform that enables eye tracking capabilities for devices with a webcam, helping developers create smarter abilities and interactivity within their applications – for any user, on any device. Tobii, the global leader in eye tr...
2024-06-20 18:00
2523
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for T...
2024-06-20 14:51
1512
GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group
* GC Cell and PT Bifarma Adiluhung announced a strategic partnership to
facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell
therapy for HCC into the Indonesian market. YONGIN, South Korea, June 19, 2024
/PRNewswire/ --GC Cell
2024-06-20 08:44
2037
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
SAN FRANCISCO, June 19, 2024 /PRNewswire/ -- Digital technology is playing a transformative role in our everyday life, shaping not only how we interact with the world around us but also ourselves. The impact of this trend is most prevalent when examining the wellness landscape, where consumers co...
2024-06-20 00:00
2247
CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A
ATLANTA, June 19, 2024 /PRNewswire/ -- The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has formed a strategic partnership with ReviR Therapeutics to advance small molecule therapeutics that modulate the expressio...
2024-06-19 21:00
1775
Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. * Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/...
2024-06-19 19:30
1975
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
SHANGHAI, June 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announcedChina's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in...
2024-06-19 19:00
1905
Ping An Announces Brand Upgrade of "Ping An Family Doctor"
HONG KONG and SHANGHAI, June 19, 2024 /PRNewswire/ -- The "Ping An Family Doctor Brand Upgrade Conference" was held inShanghai recently. Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has upgraded its "Ping An Family Doctor" ...
2024-06-19 18:15
4141
Diabetes Researchers in China Demonstrate Early Insulin Therapy Significant Benefits Cardiovascular Health
BEIJING, June 19, 2024 /PRNewswire/ -- Recently, Professor Jianping Weng of the University of Science and Technology ofChina (USTC) and President of Anhui Medical University and his team of researchers from USTC, Southern Medical University and Peking University published the results of their lat...
2024-06-19 18:10
1577
Smartee Presents Two Decades of Progress at the 99th EOS Congress in Athens
ATHENS, Greece, June 19, 2024 /PRNewswire/ -- Smartee Denti-Technology, a pioneer in clear aligner industry with 20 years of independent research & development and over 850 patents applied, shared its two decades of achievement and full series of products at the 99th Congress of the European Orth...
2024-06-19 16:44
1452
Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report
Emerging standouts set to transform drug discovery and development, revolutionize cancer treatment, and capture big pharma interest highlighted in third annual report LONDON, June 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has re...
2024-06-19 15:00
1572
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5902
